Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous …
Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …
increasingly used in routine clinical practice because of their fixed dosing and favourable …
Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis
BJR Buckley, DA Lane, P Calvert, J Zhang… - Journal of clinical …, 2022 - mdpi.com
Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …
High fluctuation between anticoagulants, frequent off-label dosing, and no difference concerning outcomes: results of a real-life cohort study
CM Eschler, A Antelo, GC Funk, AK Exadaktylos… - The American journal of …, 2021 - Elsevier
Background Recently published studies indicated a high proportion of patients taking direct
oral anticoagulants (DOACs) are off-label under-or overdosed. The present study aimed at …
oral anticoagulants (DOACs) are off-label under-or overdosed. The present study aimed at …
Apixaban for extended treatment of venous thromboembolism
Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …
dose regimen, may be an option for the extended treatment of venous thromboembolism …
Meta-analysis on risk of bleeding with apixaban in patients with renal impairment
Apixaban is a novel oral anticoagulant which is approved for the management of atrial
fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding …
fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding …
Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry
S Helmert, S Marten, H Mizera, A Reitter… - Journal of Thrombosis …, 2017 - Springer
The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
KP Cabral, J Ansell - Nature Reviews Cardiology, 2012 - nature.com
Safe and effective stroke prevention in atrial fibrillation (AF) is crucial as the number of
patients with this condition continues to increase. Several novel oral anticoagulants are …
patients with this condition continues to increase. Several novel oral anticoagulants are …
A systematic review and adjusted indirect comparison of oral anticoagulants
J Cui, B Wu, C Liu, Z Li - Orthopedics, 2014 - journals.healio.com
Educational objectives As a result of reading this article, physicians should be able to: 1.
Recognize the high risk of postoperative venous thromboembolism (VTE) in patients …
Recognize the high risk of postoperative venous thromboembolism (VTE) in patients …
New oral anticoagulants–a review
BACKGROUND Dabigatran, rivaroxaban and apixaban are three new oral anticoagulants
that have recently been approved in Norway. The aim of this article is to provide an overview …
that have recently been approved in Norway. The aim of this article is to provide an overview …